B. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20
Unicycive Therapeutics
Unicycive Therapeutics UNCY | 0.00 |
B. Riley Securities analyst Mayank Mamtani reiterates Unicycive Therapeutics (NASDAQ:
UNCY) with a Buy and lowers the price target from $22 to $20.
